| 凝血酶抑制剂比伐卢定的临床应用 |
| |
| 引用本文： | 何燕,王良友.凝血酶抑制剂比伐卢定的临床应用[J].中国临床药理学与治疗学,2013,18(3):339-343. |
| |
| 作者姓名： | 何燕 王良友 |
| |
| 作者单位： | 1. 苏州大学医学部放射医学与防护学院,苏州215123,江苏
2. 苏州中科天马肽工程中心有限公司,苏州215101,江苏 |
| |
| 基金项目： | 江苏省"大学生实践创新训练计划"项目(项目编号：5731504610) |
| |
| 摘 要： | 比伐卢定是2000年被FDA批准上市的抗凝血药物,它通过直接抑制凝血酶发挥抗凝作用,已被批准应用于PCI／PTCA、HIT／HITTS、ACS等领域。现有研究表明比伐卢定在临床抗凝治疗中有较好的安全性,可以用于常规治疗方案（肝素与糖蛋白IIb／IIIa抑制剂）的替代治疗,而且可以降低出血风险和死亡率。本文主要介绍凝血酶直接抑制剂比伐卢定的药理作用及临床研究,总结分析其安全性及经济效益,并且结合国内临床应用情况,分析其在国内的临床运用前景。
|
| 关 键 词： | 比伐卢定 凝血酶抑制剂 临床研究 经济效益 |
Inhibitor of thrombin, bivalirudin |
| |
| HE Yan,WANG Liang-you.Inhibitor of thrombin, bivalirudin[J].Chinese Journal of Clinical Pharmacology and Therapeutics,2013,18(3):339-343. |
| |
| Authors: | HE Yan WANG Liang-you |
| |
| Institution: | 1 Institute of Radiologica! Medicine and Protection, Suzhow University, Suzhou 215123, Jiangsu, China 2 Peptide Engineering Center of Suzhou Zhongke Tianma Co. Ltd,Suzhou 215101 ,Jiangsu, China |
| |
| Abstract: | Bivalirudin was approved by US Food and Drug Administration as a new direct inhibitor of thrombin in 2000, the drug was cur- rently approved the application to PCI / PTCA, HIT / HITTS, ACS etc. Existing research shows bivalirudin have a better security and can be used for the classic treatment regimens （ hep- arin and glycoprotein IIb/IIIa inhibitors ） alter- native treatment, Moreover, it can reduce the risk of bleeding and mortality. This paper analy-sis the mechanism of action, pharmacokinetics, pharmacodynamics, clinical application, safety and cost-effectiveness of bivalirudin. But it lim- ited in application in the domestic market, thus strengthening the clinical trails research is prom- is~ng. |
| |
| Keywords: | Bivalirudin Direct inhibitor ofthrombin Clinical trail Cost-Effectiveness |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
